2-HOBA in Systemic Lupus Erythematosus

This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE. 42 patients with stable SLE will be randomized to treatment sequence to receive placebo or 500mg 2-HOBA three times a day for 8 weeks followed by a 4 week washout and then 8 weeks of the other agent. Primary outcome measures include change in 24-hour blood pressure and NETosis. This study will provide mechanistic information on the role of IsoLGs in autoimmune disease-associated hypertension and immune activation.

NCT Number	NCT07225543
Lead Sponsor	Vanderbilt University Medical Center Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Systemic Lupus Erthematosus (SLE)
Enrollment	42 participants
Start Date	2026-05-15
Primary Completion	2030-07-31 (estimated)
Study Completion	2030-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-22